New insider activity at MoonLake Immunotherapeutics ( (MLTX) ) has taken place on October 9, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CFO Matthias Bodenstedt has made a significant investment in MoonLake Immunotherapeutics by purchasing 10,870 shares of the company’s stock, valued at $98,808.
Recent Updates on MLTX stock
MoonLake Immunotherapeutics experienced significant stock price adjustments following the release of mixed results from its Phase 3 VELA study on sonelokimab for hidradenitis suppurativa. Oppenheimer reduced its price target due to the drug’s inability to establish a competitive edge over BIMZELX, despite seeing potential in other indications like palmoplantar pustulosis. H.C. Wainwright downgraded the stock, citing the drug’s perceived inferiority to Bimzelx. Goldman Sachs also downgraded the stock, noting weakened commercial potential. Needham highlighted a higher placebo effect as a reason for the trial’s primary endpoint miss, while Guggenheim removed the stock as a Best Idea but acknowledged ongoing studies in other indications. These developments have led to a reassessment of the drug’s regulatory and commercial pathways, impacting the stock’s valuation.
Spark’s Take on MLTX Stock
According to Spark, TipRanks’ AI Analyst, MLTX is a Neutral.
MoonLake Immunotherapeutics presents a high-risk, high-reward scenario typical for early-stage biotech firms. The strong balance sheet and recent financing provide a solid financial foundation, but the lack of revenue and operational losses weigh heavily on the score. Technical indicators are mixed, and the negative valuation metrics reflect the developmental nature of the company. The significant financing event is a positive catalyst, enhancing the company’s ability to advance its pipeline.
To see Spark’s full report on MLTX stock, click here.
More about MoonLake Immunotherapeutics
YTD Price Performance: -83.01%
Average Trading Volume: 3,520,048
Technical Sentiment Signal: Sell
Current Market Cap: $596.1M